Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)33.44
  • Today's Change-0.12 / -0.36%
  • Shares traded430.95k
  • 1 Year change+10.00%
  • Beta1.0445
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The Company is also engaged in the research and development of pharmaceutical production processes. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)1.03bn
  • Net income in HKD-189.14m
  • Incorporated2009
  • Employees1.11k
  • Location
    CanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
  • Phone+86 2 258213766
  • Fax+86 2 258213626
  • Websitehttps://www.cansinotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Shineway Pharmaceutical Group Ltd3.79bn938.05m8.03bn2.87k7.820.907910.302.121.241.245.0110.700.32991.153.811,176,221.008.178.2910.7510.3873.3674.8324.7718.673.39--0.041937.49-16.356.90-13.3510.808.9219.39
CStone Pharmaceuticals229.34m-427.09m8.74bn93.00--22.64--38.10-0.3277-0.32770.1770.26150.14871.381.681,698,809.00-27.69-39.13-54.45-60.19-12.1866.69-186.23-170.861.20-29.830.554---12.21--75.16------
SSY Group Ltd4.58bn658.92m8.78bn5.70k13.591.237.821.920.2230.2231.552.460.36162.272.11751,065.605.279.416.3412.4342.6856.4714.5817.652.4014.910.34642.91-10.674.49-19.53-1.36-8.369.73
Hbm Holdings Ltd904.42m571.13m10.17bn210.0015.794.2017.0011.240.74060.74061.142.780.38566.3232.645,797,568.0024.77-42.8730.77-53.2492.9596.1264.25-292.586.0228.630.1857---57.4347.71-87.81---55.31--
China Traditional Chinese Med Hldg CoLtd17.65bn-299.94m10.27bn15.58k--0.438111.290.5819-0.0596-0.05963.514.660.43261.591.711,053,804.00-0.933.48-1.425.2447.6654.69-2.157.391.519.550.133321.27-8.902.89-95.79-49.14-15.28-48.82
Fujian Haixi Pharmaceuticals Co Ltd-100.00bn-100.00bn10.74bn--------------------------------------------------47.39--15.86------
Luye Pharma Group Ltd6.99bn449.57m10.79bn5.12k22.590.61046.731.540.11950.11951.864.420.20832.422.371,356,462.001.911.983.263.1666.8568.379.158.041.242.350.42270.00-1.33-0.9503-11.40-19.50-10.95--
Cansino Biologics Inc1.03bn-189.14m12.71bn1.11k--1.49706.2812.29-0.766-0.7664.1922.480.11540.65521.45936,361.40-2.11-4.08-2.74-5.4075.5238.74-18.28-27.692.28--0.2781--138.97--74.45--31.37--
Guangzhou Innogen Pharmaceutl Grp Co Ltd-100.00bn-100.00bn12.76bn105.00--15.00----------1.84------------------------3.39--0.0769------76.18------
Everest Medicines Ltd964.16m-746.10m13.86bn722.00--2.89--14.38-2.31-2.312.9813.570.168413.973.041,449,858.00-13.03-29.28-14.21-31.6769.92---77.38-1,040.865.43--0.1577--461.16---23.32--16.96--
CF PharmTech Inc684.00m31.43m14.21bn574.00452.4113.10138.3620.780.07630.07631.662.64----------------80.18--4.60--1.89--0.076--9.23---33.53------
Sihuan Pharmaceutical Holdings Group Ltd2.38bn-91.33m14.91bn2.77k--3.02--6.28-0.0098-0.00980.25750.54020.18941.493.86890,789.90-3.05-3.60-5.01-5.0566.2973.13-16.08-19.741.61-1.360.1606--2.18-7.96-301.10---20.583.60
Consun Pharmaceutical Group Ltd3.70bn1.14bn15.22bn3.07k13.593.1312.494.111.331.334.315.780.56422.3512.331,169,558.0017.6014.7124.6722.8276.6275.0431.2029.563.32--0.051740.9314.5611.4216.0562.72-9.5425.83
Ascletis Pharma Inc2.68m-292.85m17.42bn208.00--7.48--6,507.62-0.2994-0.29940.00282.200.00110.266811.5911,590.66-12.10-8.46-12.73-8.8036.217.91-10,937.78-522.1214.53--0.0023---97.73-62.52-107.95---40.26--
Data as of Feb 13 2026. Currency figures normalised to CanSino Biologics Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.01%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Jan 20263.43m2.58%
GF Fund Management Co., Ltd.as of 30 Jun 20251.82m1.37%
BlackRock Fund Advisorsas of 09 Jan 20261.06m0.80%
China Universal Asset Management Co., Ltd.as of 30 Jun 20251.02m0.77%
Capital Research & Management Co. (World Investors)as of 31 Dec 2025864.52k0.65%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025614.40k0.46%
Fullgoal Asset Management (HK) Ltd.as of 30 Jun 2025583.20k0.44%
Dimensional Fund Advisors LPas of 08 Jan 2026446.00k0.34%
BlackRock Advisors (UK) Ltd.as of 09 Jan 2026434.40k0.33%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2025367.40k0.28%
More ▼
Data from 30 Jun 2025 - 21 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.